Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside

Physiologically Based Mathematical Models to Optimize Therapies Against Metastatic Colorectal Cancer: A Mini-Review

(2014) Annabelle Ballesta et al.   CURRENT PHARMACEUTICAL DESIGN

Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies

(2014) Mohammad Hojjat-Farsangi   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

ALK inhibitors in the treatment of advanced NSCLC

(2013) Cesare Gridelli et al.   CANCER TREATMENT REVIEWS

Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development

(2013) P A Milligan et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Utility of Modeling and Simulation in Drug Development and Regulatory Review

(2013) Shiew-Mei Huang et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors

(2013) D. C. Kirouac et al.   Science Signaling

ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC

(2013) Francesca Casaluce et al.   Targeted Oncology

Translational Pharmacokinetic-Pharmacodynamic Modeling from Nonclinical to Clinical Development: A Case Study of Anticancer Drug, Crizotinib

(2012) Shinji Yamazaki   AAPS Journal

Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response

(2012) H. Wong et al.   CLINICAL CANCER RESEARCH

The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review

(2012) S-M Huang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development

(2012) Apexa Bernard et al.   Expert Opinion on Drug Metabolism & Toxicology

Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer

(2012) Sai-Hong Ignatius Ou   Expert Review of Anticancer Therapy

Pharmacokinetic-Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation

(2011) H. Wong et al.   CLINICAL CANCER RESEARCH

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

(2011) Paul Morgan et al.   DRUG DISCOVERY TODAY

Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available Heat Shock Protein 90 Inhibitor in a Human Tumor Xenograft Mouse Model

(2011) S. Yamazaki et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

(2011) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

Phase II failures: 2008–2010

(2011) John Arrowsmith   NATURE REVIEWS DRUG DISCOVERY

ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time

(2010) David E. Gerber et al.   CANCER CELL

Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941

(2010) L. Salphati et al.   DRUG METABOLISM AND DISPOSITION

Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models

(2010) S. Daouti et al.   MOLECULAR CANCER THERAPEUTICS

The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery

(2010) Dennis A. Smith et al.   NATURE REVIEWS DRUG DISCOVERY

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor

(2010) Edna F. Choo et al.   XENOBIOTICA

Comparison of Two Pharmacodynamic Transduction Models for the Analysis of Tumor Therapeutic Responses in Model Systems

(2009) Jun Yang et al.   AAPS Journal

Cancer systems biology: a network modeling perspective

(2009) P. K. Kreeger et al.   CARCINOGENESIS

Authors' Response

(2009) Shiew-Mei Huang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacodynamics of 2- ethan-1-ol (GDC-0879), a Potent and Selective B-Raf Kinase Inhibitor: Understanding Relationships between Systemic Concentrations, Phosphorylated Mitogen-Activated Protein Kinase Kinase 1 Inhibition, and Efficacy

(2009) H. Wong et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Dose Escalation Methods in Phase I Cancer Clinical Trials

(2009) Christophe Le Tourneau et al.   JNCI-Journal of the National Cancer Institute

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

(2008) R. Plummer et al.   CLINICAL CANCER RESEARCH

Pharmacokinetic and Pharmacodynamic Data to be Derived from Early-Phase Drug Development

(2008) Adam Cohen   CLINICAL PHARMACOKINETICS

Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models

(2008) S. Yamazaki et al.   DRUG METABOLISM AND DISPOSITION

Antitumor Efficacy Testing in Rodents

(2008) Melinda G. Hollingshead   JNCI-Journal of the National Cancer Institute

Do molecularly targeted agents in oncology have reduced attrition rates?

(2008) Ian Walker et al.   NATURE REVIEWS DRUG DISCOVERY

Signaling networks assembled by oncogenic EGFR and c-Met

(2008) A. Guo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice

(2007) Lorea Bueno et al.   EUROPEAN JOURNAL OF CANCER